FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Oppenheimer analyst Jay Olson reiterated a Perform rating and $20.00 price target on Sage Therapeutics (NASDAQ: SAGE)
The analyst comments "SAGE is focused on delivering newly-approved Zurzuvae to PPD patients while accelerating development of pipeline assets and rationalizing OpEx spending. We... More
SAGE Therapeutics (NASDAQ: SAGE) sinks 47% as trading resumes after FDA approval for ZURZUVAETM in postpartum depression (PPD) but a CRL for major depressive disorder (MDD).
... More

